Mowshowitz S L, Chin-Bow S T, Smith G D
J Interferon Res. 1982;2(4):587-91. doi: 10.1089/jir.1982.2.587.
CDF1 mice were implanted with 10(6) P388 leukemia cells. One day postimplantation, when interferon (IFN) therapy was begun, the tumor burden was ca. 4.8 X 10(6) cells. Therapy consisted of nine consecutive daily intraperitoneal (i.p.) injections of 10(6) units of Ehrlich ascites tumor cell IFN (specific activity 5 X 10(7) IU/mg). The median life span for control animals was 10.0 days versus 18.5 days for the treated animals. It was estimated that about 2 X 10(6) viable P388 cells were present on Day 9 when therapy was discontinued. There was no evidence of toxicity in animals receiving 10(6) units of IFN/day for nine consecutive days. In a separate experiment, control animals challenged as above had a median life span of 9.5 days of versus 15 days for animals receiving 10(6) units of IFN qd on Days 2-10. A third group of animals receiving a single injection of cis-DDP on Day 1 had a median survival of 18.5 days, while a fourth group receiving both cis-DDP on Day 1 and subsequent treatment with IFN survived 26 days. The results are discussed in terms of impact on tumor cell population.
将10⁶个P388白血病细胞植入CDF1小鼠体内。植入后一天，当开始干扰素（IFN）治疗时，肿瘤负荷约为4.8×10⁶个细胞。治疗包括连续九天每天腹腔注射10⁶单位的艾氏腹水瘤细胞干扰素（比活性为5×10⁷IU/mg）。对照动物的中位生存期为10.0天，而治疗动物为18.5天。据估计，在第9天停止治疗时，约有2×10⁶个存活的P388细胞。连续九天每天接受10⁶单位干扰素的动物没有毒性迹象。在另一项实验中，如上所述接受挑战的对照动物的中位生存期为9.5天，而在第2 - 10天每天接受10⁶单位干扰素的动物为15天。第三组动物在第1天接受单次顺铂注射，中位生存期为18.5天，而第四组在第1天接受顺铂并随后接受干扰素治疗，存活了26天。从对肿瘤细胞群体的影响方面对结果进行了讨论。
